{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:04:30Z","timestamp":1782252270493,"version":"3.54.5"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T00:00:00Z","timestamp":1458086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jacl.2016.02.018","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T01:46:04Z","timestamp":1458006364000},"page":"860-869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"10","author":[{"given":"Frederick J.","family":"Raal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjet J.","family":"Braamskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl L.","family":"Selvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte H.","family":"Sensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jacl.2016.02.018_bib1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2016.02.018_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2016.02.018_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2016.02.018_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40272-013-0060-2","article-title":"Management of hypercholesterolemia in children","volume":"16","author":"Braamskamp","year":"2014","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jacl.2016.02.018_bib5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1517\/21678707.2014.958467","article-title":"The role of rosuvastatin in the treatment of pediatric homozygous familial hypercholesterolemia","volume":"12","author":"Braamskamp","year":"2014","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.jacl.2016.02.018_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/TACG.S44315","article-title":"The genetics of familial hypercholesterolemia and emerging therapies","volume":"8","author":"Vogt","year":"2015","journal-title":"Appl Clin Genet"},{"issue":"3","key":"10.1016\/j.jacl.2016.02.018_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2016.02.018_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2011.547471","article-title":"Mipomersen, an antisense apolipoprotein B synthesis inhibitor","volume":"20","author":"Bell","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jacl.2016.02.018_bib9","series-title":"Kynamro [package insert]","year":"2013"},{"issue":"9719","key":"10.1016\/j.jacl.2016.02.018_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2016.02.018_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2016.02.018_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase iii trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"36","key":"10.1016\/j.jacl.2016.02.018_bib13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"Suppl\u00a02","key":"10.1016\/j.jacl.2016.02.018_bib14","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/ar996","article-title":"Does route of administration affect the outcome of TNF antagonist therapy?","volume":"6","author":"Schwartzman","year":"2004","journal-title":"Arthritis Res Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415300842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T09:51:53Z","timestamp":1536918713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415300842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1933287415300842"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.02.018","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sanofi-Genzyme. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}